Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

NCT05313022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: ZR-202-CoV
OTHER: Placebo

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd

Collaborators

[object Object]